Crescent Biopharma to Present at May Investor Conferences
Rhea-AI Summary
Crescent Biopharma (Nasdaq: CBIO) announced management presentations at three investor conferences in May 2026: BofA Securities Healthcare Conference (fireside chat, May 13), Stifel Virtual Targeted Oncology Forum (virtual fireside chat, May 20), and Cowen Oncology Innovation Summit (virtual fireside chat, May 26).
A live webcast will be available in the Investors section of Crescent's website and replays will be accessible for 90 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CBIO
In the May 6 session, CBIO declined 0.11%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- BofA conference date
- May 13, 2026
- BofA Securities 2026 Healthcare Conference fireside chat
- BofA session time
- 4:20 p.m. PT
- Scheduled time for BofA conference fireside chat
- Stifel forum date
- May 20, 2026
- Stifel Virtual Targeted Oncology Forum fireside chat
- Stifel session time
- 2:30 p.m. ET
- Scheduled time for Stifel virtual fireside chat
- Cowen summit date
- May 26, 2026
- TD Cowen 7th Annual Oncology Innovation Summit session
- Cowen session time
- 11:30 a.m. ET
- Scheduled time for Cowen oncology innovation fireside chat
- Webcast replay window
- 90 days
- Replay availability for conference webcasts on investor site
- Pre‑news share price
- $18.08
- Price before May 6, 2026 conference announcement
Historical Context
-
Reported Q1 2026 results, cash of $189.2M, and pipeline timelines into 2027.
-
Granted options over 12,525 shares with 10‑year term and $25.70 exercise price.
-
Awarded options for 35,325 shares at $13.50, vesting over four years.
-
Announced 45,675 option shares at $11.33 with standard 10‑year term and vesting.
-
Reported 2025 results, Kelun partnership, CR‑001 IND clearance, and $185M private placement.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 06, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in May:
- BofA Securities 2026 Healthcare Conference, fireside chat on Wednesday, May 13, 2026 at 4:20 p.m. PT (7:20 p.m. ET) in Las Vegas
- 2026 Stifel Virtual Targeted Oncology Forum, virtual fireside chat on Wednesday, May 20, 2026 at 2:30 p.m. ET
- TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA, virtual fireside chat on Tuesday, May 26, 2026 at 11:30 a.m. ET
A live webcast of each presentation will be available in the Investors section of Crescent's website at https://investors.crescentbiopharma.com/events-presentations, and a replay will be accessible for 90 days.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies either as single agents or as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Contacts
Investors
Amy Reilly
Chief Communications Officer
amy.reilly@crescentbiopharma.com
617-465-0586
Media
Jenna Poist
Director, Corporate Communications
jenna.poist@crescentbiopharma.com
781-671-5019
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.